Transcription of CONTRAINDICATIONS--------------------------
{{id}} {{{paragraph}}}
HIGHLIGHTS OF PRESCRIBING INFORMATIONT hese highlights do not include all the information needed to use vidaza safely and effectively. See full prescribing information for vidaza . vidaza (azacitidine for injection), for subcutaneous or intravenous useInitial Approval: 2004---------------------------RECENT MAJOR CHANGES---------------------------Dosage and Administration ( )7/2018----------------------------INDIC ATIONS AND USAGE--------------------------- vidaza is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VIDAZA safely and effectively. …
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}